Skip to content
Screener

Incyte INCY Q2 2026 earnings

Reported July 28, 2026 · Before market open

Revenue$1.7BBeat by $170.1M
EPS$3.09Beat by $0.94
Revenue estimate$1.5B
EPS estimate$2.15
“Every marketed product contributed to growth, reflecting the strength of our commercial portfolio and execution. We also recently strengthened our Hematology franchise through the acquisition of latarcibart, a potentially transformative medicine for von Willebrand disease currently in Phase 3 development. With ten data readouts expected in the second half of 2026, alongside product launches through early next year, we are well positioned for our next phase of growth.”
Bill Meury

Next report

Oct 27, 2026 (in 2 months)
Revenue estimate$1.5B
EPS estimate-$2.83

Financials

Q2 2026

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
Free cash flow$509.3M+1,069%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$25.97B+56.8%
Enterprise value$22.02B+50.3%
P/E16.1×-2.9×
P/S4.5×+0.8×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0×0.0×
Current ratio4.6×+1.7×

Segments

By product

See full
JAKAFI$816.7M+6.9%
OPZELURA$449.7M+173%
JAKAVI Royalty Revenues$124.2M+13.2%
NIKTIMVO$60.3M+66.8%
MINJUVI/MONJUVI$53.7M+72.5%

By geography

See full
Europe$105.1M+33.4%
Other countries$8.8M+102%

By segment

See full
Reportable Segment$1.7B+37.7%

FAQ

When did Incyte report Q2 2026 earnings?
Incyte (INCY) reported Q2 2026 earnings on July 28, 2026 before market open.
What were Incyte's Q2 2026 revenue and EPS?
Incyte reported revenue of $1.7B and eps of $3.09 for Q2 2026.
Did Incyte beat estimates in Q2 2026?
Revenue beat the consensus estimate of $1.5B by $170.1M. EPS beat the consensus estimate of $2.15 by $0.94.
How did Incyte's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 37.7% from $1.2B a year earlier and eps grew 96.8% from $1.57.
Where can I find Incyte's Q2 2026 SEC filings?
You can read the 8-K earnings release (0000879169-26-000053) and the 10-Q periodic report (0000879169-26-000056) directly on SEC EDGAR. The filing index links above go to sec.gov.